Last updated: February 14, 2026
Overview of the Product
NDC 42571-0226 corresponds to Brolucizumab-dbll, marketed as Beovu by Novartis. It is approved for the treatment of neovascular (wet) age-related macular degeneration (AMD). Approved by the FDA in October 2019, Beovu's mechanism involves inhibiting vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth in the retina.
Market Size and Penetration
The wet AMD market primarily includes patients aged 50 and above. According to the CDC, approximately 11 million Americans have some form of AMD, with 1.5 million affected by wet AMD. The global market size is valued at around $4 billion as of 2022, with continued growth driven by aging populations and increased screening.
Competitive Landscape
Key competitors include:
- Ranibizumab (Genentech/Roche) — Lucentis
- Aflibercept (Bayer/Regeneron) — Eylea
- Faricimab (Roivant Sciences) — Vabysmo (approved in 2022)
Beovu differentiates through its extended dosing interval, allowing for up to three months between injections in some cases, potentially improving patient adherence and reducing treatment costs.
Pricing Analysis
The average wholesale price (AWP) for Beovu is approximately $2,100 per injection. Contract prices, rebates, and insurance negotiations can lower actual costs to providers, typically resulting in net prices around $1,500-$1,700.
Pricing Compared to Competitors
| Drug |
Average Wholesale Price (per injection) |
Dosing Frequency |
Market Share (2022) |
Notes |
| Beovu |
$2,100 |
Every 8-12 weeks |
~10% |
Extended dosing may reduce total treatment costs |
| Lucentis |
$2,200 |
Monthly or bi-monthly |
~50% |
Older standard, more frequent injections |
| Eylea |
$2,000 |
Every 8 weeks |
~30% |
Similar extended interval, cost-effective |
| Vabysmo (Faricimab) |
~$2,300 |
Monthly or every 8-16 weeks |
Emerging |
Novel bispecific antibody, potential to disrupt existing market |
Market Penetration and Growth Projections
Forecasts suggest a compound annual growth rate (CAGR) of 4-6% over the next five years, driven by:
- Increased prevalence of AMD
- Adoption of extended dosing regimens
- Replacement of older therapies
The market is expected to reach approximately $5.5-$6 billion globally by 2027.
Price Projections
- Short-term (1-2 years): The per-injection price remains near current levels (~$2,100), with signing of managed care contracts influencing net prices.
- Medium-term (3-5 years): Market competition, biosimilar entry, and value-based pricing models could reduce prices marginally by 5-10%.
- Long-term (beyond 5 years): Technological advances and biosimilar development may lower prices further, potentially to ~$1,500-$1,700 per injection.
Regulatory and Policy Impacts
Insurance coverage policies and healthcare reforms can influence pricing. For instance, increased formulary restrictions or value-based reimbursement models may put additional downward pressure on prices.
Conclusion
NDC 42571-0226 (Beovu) holds approximately 10% of the wet AMD market. The current average price per injection is around $2,100, with limited short-term reductions expected but potential declines in the longer term due to competition. The overall market continues to grow, supported by demographic trends and evolving treatment paradigms.
Key Takeaways
- Beovu's price per injection (~$2,100) faces little immediate downward pressure but is susceptible to long-term reductions from biosimilar entry and market competition.
- The global wet AMD market is valued at about $4 billion, with annual growth of 4-6%.
- Competition from Lucentis, Eylea, and emerging agents influences market share and pricing strategies.
- Extended dosing intervals may lead to higher adherence and better cost-efficiency, supporting product market position.
- Healthcare policies and insurer negotiations significantly impact actual transaction prices.
FAQs
1. What factors influence the pricing of Beovu?
Pricing is affected by manufacturing costs, market competition, negotiated rebates, insurance coverage, and formulary positioning.
2. How does Beovu’s dosing schedule impact its market share?
Extended dosing intervals (up to three months) can improve adherence and reduce overall treatment costs, favoring wider adoption over more frequently dosed therapies.
3. Are biosimilars expected for Beovu?
As of now, biosimilar development for Beovu is not announced. However, biosimilars for similar anti-VEGF agents are in development, potentially impacting prices in the future.
4. How does Beovu compare in safety and efficacy?
Beovu has demonstrated non-inferiority in efficacy to other anti-VEGF agents. Some safety concerns, including intraocular inflammation, have influenced prescribing practices but do not significantly limit its market presence.
5. What are the barriers to price reductions in this market?
Limited patent expirations, high development and manufacturing costs, and the necessity for clinical efficacy sustain current prices. Market entry of biosimilars depends heavily on regulatory and patent challenges.
Citations
[1] IQVIA. "Global Ophthalmology Market Analysis," 2022.
[2] FDA. "Beovu (brolucizumab-dbll) Approval Letter," 2019.
[3] Alcon, "Market Share Data for AMD Treatments," 2022.
[4] Deloitte. "Pharmaceutical Pricing Trends," 2022.
[5] Statista. "Age-related Macular Degeneration (AMD) Market Size," 2022.
